Discovery Of Single Agents To Treat Chagas Disease And Human African Trypanosomiasis
Funder
National Health and Medical Research Council
Funding Amount
$527,189.00
Summary
In this project we aim to discover new drugs to treat Chagas disease and human African trypanosomiasis. These debilitating parasitic diseases are neglected by pharmaceutical companies and afflict millions of impoverished people worldwide. We aim to be able to treat both diseases with a single agent
Microparticles And Selective Trait Dominance In Multidrug Resistant Cancers
Funder
National Health and Medical Research Council
Funding Amount
$478,115.00
Summary
Multidrug resistance (MDR) is the cause of treatment failure in 90% of patients with metastatic cancer. We recently discovered a novel resistance mechanism in which microparticles provide a vehicle for intercellular transfer of MDR. We now report that MP play an even more significant role in conferring MDR, by the ñre-templatingî of cancer cell traits. This has considerable potential for translation into clinical outcomes with the identification of alternative drug targets and therapeutics for t ....Multidrug resistance (MDR) is the cause of treatment failure in 90% of patients with metastatic cancer. We recently discovered a novel resistance mechanism in which microparticles provide a vehicle for intercellular transfer of MDR. We now report that MP play an even more significant role in conferring MDR, by the ñre-templatingî of cancer cell traits. This has considerable potential for translation into clinical outcomes with the identification of alternative drug targets and therapeutics for the circumvention of MDR clinically.Read moreRead less
Phosphonated Calixarenes For The Targeted Intracellular Delivery Of Anticancer Agents
Funder
National Health and Medical Research Council
Funding Amount
$322,267.00
Summary
Many anticancer drugs have severe side effects due to their potency and non-specificity of action. To improve the treatment outcome for thousands of cancer patients, we aim to engineer calixarene-based nanocarriers that bypass normal tissues to selectively deposit drugs and imaging agents into tumour cells. Such delivery systems will optimize the performance of a host of anticancer agents that act within cells, and enable drug treatment and monitoring to be simultaneously realised.